Junqiang Lv

658 total citations
28 papers, 478 citations indexed

About

Junqiang Lv is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Junqiang Lv has authored 28 papers receiving a total of 478 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 9 papers in Oncology and 6 papers in Immunology. Recurrent topics in Junqiang Lv's work include Peptidase Inhibition and Analysis (5 papers), Cancer Mechanisms and Therapy (4 papers) and Cancer, Hypoxia, and Metabolism (3 papers). Junqiang Lv is often cited by papers focused on Peptidase Inhibition and Analysis (5 papers), Cancer Mechanisms and Therapy (4 papers) and Cancer, Hypoxia, and Metabolism (3 papers). Junqiang Lv collaborates with scholars based in China, United States and Saudi Arabia. Junqiang Lv's co-authors include Zhi Yao, Quan Wang, Rong Lu, Zhi‐Song Zhang, Huali Zhang, Lijuan Chen, Xiaolei Li, Rui Ma, Lı Wang and Yanjiao Zhou and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and Blood.

In The Last Decade

Junqiang Lv

25 papers receiving 468 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Junqiang Lv China	13	258	77	58	57	56	28	478
Jae-We Cho South Korea	13	359 1.4×	64 0.8×	65 1.1×	119 2.1×	61 1.1×	30	904
Haiting Xu China	15	316 1.2×	38 0.5×	54 0.9×	72 1.3×	41 0.7×	33	791
Ge Peng Japan	16	300 1.2×	103 1.3×	43 0.7×	141 2.5×	86 1.5×	39	831
Hongbo Xu China	12	272 1.1×	38 0.5×	68 1.2×	97 1.7×	23 0.4×	31	540
Achchhe Lal Vishwakarma India	12	202 0.8×	99 1.3×	109 1.9×	71 1.2×	18 0.3×	14	505
Regina Weinmüllner Austria	7	186 0.7×	106 1.4×	56 1.0×	75 1.3×	22 0.4×	8	573
Jack Kao United States	6	243 0.9×	98 1.3×	50 0.9×	115 2.0×	51 0.9×	6	1.3k
Gholam Basati Iran	14	259 1.0×	62 0.8×	72 1.2×	51 0.9×	22 0.4×	46	562
Su‐Ying Wen Taiwan	15	206 0.8×	52 0.7×	63 1.1×	91 1.6×	14 0.3×	35	744
Cristina L. Esteves United Kingdom	19	313 1.2×	58 0.8×	45 0.8×	77 1.4×	37 0.7×	43	931

Countries citing papers authored by Junqiang Lv

Since Specialization

Citations

This map shows the geographic impact of Junqiang Lv's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Junqiang Lv with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Junqiang Lv more than expected).

Fields of papers citing papers by Junqiang Lv

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Junqiang Lv. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Junqiang Lv. The network helps show where Junqiang Lv may publish in the future.

Co-authorship network of co-authors of Junqiang Lv

This figure shows the co-authorship network connecting the top 25 collaborators of Junqiang Lv. A scholar is included among the top collaborators of Junqiang Lv based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Junqiang Lv. Junqiang Lv is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wu, Hao, Jiajia Yang, Yan Xiao, et al.. (2025). Targeting the BCKDK/BCLAF1/MYC/HK2 axis to alter aerobic glycolysis and overcome Trametinib resistance in lung cancer. Cell Death and Differentiation. 32(12). 2210–2224. 1 indexed citations

Lu, Bowen, et al.. (2025). A galactoarabinan-containing glycoprotein isolated from the fruits of Lycium barbarum reverses the tumor-associated macrophage phenotype. Frontiers in Pharmacology. 16. 1593407–1593407.

Miao, Chunhui, Yajie Zhang, Guowen Liu, et al.. (2024). Multi-step strategies for synergistic treatment of urinary tract infections based on D-xylose-decorated antimicrobial peptide carbon dots. Biomaterials. 308. 122547–122547. 11 indexed citations

Yang, Jianming, Ningning Zhao, Yan Sun, et al.. (2024). PIM1–HDAC2 axis modulates intestinal homeostasis through epigenetic modification. Acta Pharmaceutica Sinica B. 14(7). 3049–3067. 4 indexed citations

Lv, Junqiang, Hao Sun, Xiaojing Wei, et al.. (2022). Aberrant metabolic processes promote the immunosuppressive microenvironment in multiple myeloma. Frontiers in Immunology. 13. 1077768–1077768. 19 indexed citations

Miao, Chunhui, Zhenyi Ma, Lisong Zhang, et al.. (2021). An infection-induced RhoB-Beclin 1-Hsp90 complex enhances clearance of uropathogenic Escherichia coli. Nature Communications. 12(1). 2587–2587. 15 indexed citations

Liu, Lanting, Zhen Yu, Hui Cheng, et al.. (2020). Multiple myeloma hinders erythropoiesis and causes anaemia owing to high levels of CCL3 in the bone marrow microenvironment. Scientific Reports. 10(1). 20508–20508. 33 indexed citations

Wang, Changying, Qianqian Li, Junqiang Lv, et al.. (2019). Alpha-hemolysin of uropathogenic Escherichia coli induces GM-CSF-mediated acute kidney injury. Mucosal Immunology. 13(1). 22–33. 35 indexed citations

Yang, Huan, Qianqian Li, Changying Wang, et al.. (2018). Cytotoxic Necrotizing Factor 1 Downregulates CD36 Transcription in Macrophages to Induce Inflammation During Acute Urinary Tract Infections. Frontiers in Immunology. 9. 1987–1987. 18 indexed citations

10.

Zhao, Xiujuan, Xing Wang, Qian Li, et al.. (2018). FBXL10 contributes to the development of diffuse large B-cell lymphoma by epigenetically enhancing ERK1/2 signaling pathway. Cell Death and Disease. 9(2). 46–46. 15 indexed citations

11.

Fu, Zheng, Li Ren, Huiting Wei, et al.. (2013). Effects of Tyroserleutide on phosphatidylinositol 3′-kinase/AKT pathway in human hepatocellular carcinoma cell. Journal of drug targeting. 22(2). 146–155. 13 indexed citations

12.

Wang, Lanlan, Xueying Li, Junqiang Lv, et al.. (2012). Tyroservatide therapy for tumor invasion and metastasis of human ovarian carcinoma and colon carcinoma. Anti-Cancer Drugs. 23(10). 1067–1077. 2 indexed citations

13.

Hu, Jinwei, Lijuan Wang, Zhifeng Zhu, et al.. (2011). Expression, purification, and activity assay of peptide deformylase from Escherichia coli and Staphylococcus aureus. Molecular and Cellular Biochemistry. 357(1-2). 47–54. 4 indexed citations

14.

Lv, Junqiang, Wen Zhang, Song Wang, et al.. (2010). The pentapeptide PLNPK inhibits systemic lupus erythematosus-associated renal damage. Inflammation Research. 59(12). 1081–1089. 2 indexed citations

15.

Wang, Lijuan, Song Wang, Junqiang Lv, et al.. (2010). The new immunosuppressant PLNPK prolongs allograft survival in mice. Transplant Immunology. 24(1). 64–68. 2 indexed citations

16.

Xu, Qiong, Rong Lu, Zhifeng Zhu, et al.. (2010). Effects of tyroservatide on histone acetylation in lung carcinoma cells. International Journal of Cancer. 128(2). 460–472. 16 indexed citations

17.

Wang, Chong, Song Wang, Rong Lu, et al.. (2009). Effects of a novel tripeptide, tyroserleutide (YSL), on cell cycle progression of human hepatocellular carcinoma. Anti-Cancer Drugs. 20(7). 534–542. 2 indexed citations

18.

Wang, Lı, Huali Zhang, Rong Lu, et al.. (2008). The decapeptide CMS001 enhances swimming endurance in mice. Peptides. 29(7). 1176–1182. 120 indexed citations

19.

Zhou, Chunlei, Junqiang Lv, Rong Lu, et al.. (2008). A new pentapeptide compound, PLNPK, ameliorates anti-glomerular basement membrane nephritis in Wistar rats. Peptides. 29(10). 1789–1797. 3 indexed citations

20.

Fu, Zheng, Rong Lu, Jing Jia, et al.. (2007). Inhibition of five xenografted human cancers and two murine cancers by the tripeptide tyroservatide. Anti-Cancer Drugs. 18(4). 467–470. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact